HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis
USA - NASDAQ:HZNP - IE00BQPVQZ61 - Common Stock
116.3 USD
+0.05 (+0.04%)
116.34 USD
+0.04 (+0.03%)
Overall HZNP gets a fundamental rating of 6 out of 10. We evaluated HZNP against 531 industry peers in the Biotechnology industry. HZNP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HZNP has a decent growth rate and is not valued too expensively. With these ratings, HZNP could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
HZNP had positive earnings in the past year.
In the past year HZNP had a positive cash flow from operations.
Of the past 5 years HZNP 4 years were profitable.
In the past 5 years HZNP always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of HZNP (4.71%) is better than 95.21% of its industry peers.
The Return On Equity of HZNP (8.25%) is better than 95.38% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.35%, HZNP belongs to the top of the industry, outperforming 95.87% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HZNP is significantly below the industry average of 15.55%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROIC | 5.35% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
1.3 Margins
HZNP's Profit Margin of 12.02% is amongst the best of the industry. HZNP outperforms 96.04% of its industry peers.
In the last couple of years the Profit Margin of HZNP has declined.
The Operating Margin of HZNP (15.58%) is better than 96.53% of its industry peers.
HZNP's Operating Margin has improved in the last couple of years.
HZNP's Gross Margin of 75.21% is amongst the best of the industry. HZNP outperforms 84.49% of its industry peers.
HZNP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% |
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
2. Health
2.1 Basic Checks
HZNP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
HZNP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, HZNP has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.10 indicates that HZNP is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.10, HZNP belongs to the top of the industry, outperforming 81.35% of the companies in the same industry.
HZNP has a debt to FCF ratio of 2.67. This is a good value and a sign of high solvency as HZNP would need 2.67 years to pay back of all of its debts.
HZNP's Debt to FCF ratio of 2.67 is amongst the best of the industry. HZNP outperforms 95.54% of its industry peers.
HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
HZNP has a worse Debt to Equity ratio (0.48) than 74.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Altman-Z | 5.1 |
ROIC/WACC0.75
WACC7.16%
2.3 Liquidity
HZNP has a Current Ratio of 4.27. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
HZNP has a Current ratio of 4.27. This is comparable to the rest of the industry: HZNP outperforms 41.58% of its industry peers.
A Quick Ratio of 4.09 indicates that HZNP has no problem at all paying its short term obligations.
HZNP's Quick ratio of 4.09 is in line compared to the rest of the industry. HZNP outperforms 40.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 |
3. Growth
3.1 Past
HZNP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.39%.
HZNP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.01% yearly.
HZNP shows a decrease in Revenue. In the last year, the revenue decreased by -4.42%.
The Revenue has been growing by 28.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
3.2 Future
The Earnings Per Share is expected to grow by 15.92% on average over the next years. This is quite good.
Based on estimates for the next years, HZNP will show a quite strong growth in Revenue. The Revenue will grow by 9.94% on average per year.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.90 indicates a quite expensive valuation of HZNP.
HZNP's Price/Earnings ratio is rather cheap when compared to the industry. HZNP is cheaper than 95.54% of the companies in the same industry.
When comparing the Price/Earnings ratio of HZNP to the average of the S&P500 Index (26.28), we can say HZNP is valued inline with the index average.
HZNP is valuated rather expensively with a Price/Forward Earnings ratio of 20.14.
Based on the Price/Forward Earnings ratio, HZNP is valued cheaply inside the industry as 96.53% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HZNP to the average of the S&P500 Index (33.61), we can say HZNP is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HZNP is valued cheaper than 94.88% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HZNP is valued cheaper than 96.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.79 | ||
| EV/EBITDA | 27.94 |
4.3 Compensation for Growth
The excellent profitability rating of HZNP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%
5. Dividend
5.1 Amount
No dividends for HZNP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
116.3
+0.05 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Revenue(TTM)3.64B
Net Income(TTM)438.00M
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 | ||
| P/S | 7.31 | ||
| P/FCF | 27.79 | ||
| P/OCF | 25.59 | ||
| P/B | 5.01 | ||
| P/tB | 26.53 | ||
| EV/EBITDA | 27.94 |
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROCE | 6.77% | ||
| ROIC | 5.35% | ||
| ROICexc | 7.58% | ||
| ROICexgc | 27.86% | ||
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% | ||
| FCFM | 26.3% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexgc growth 3Y27.62%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Debt/EBITDA | 2.66 | ||
| Cap/Depr | 21.15% | ||
| Cap/Sales | 2.26% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 108.78% | ||
| Profit Quality | 218.81% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 | ||
| Altman-Z | 5.1 |
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%
HORIZON THERAPEUTICS PLC / HZNP FAQ
What is the fundamental rating for HZNP stock?
ChartMill assigns a fundamental rating of 6 / 10 to HZNP.
What is the valuation status of HORIZON THERAPEUTICS PLC (HZNP) stock?
ChartMill assigns a valuation rating of 5 / 10 to HORIZON THERAPEUTICS PLC (HZNP). This can be considered as Fairly Valued.
How profitable is HORIZON THERAPEUTICS PLC (HZNP) stock?
HORIZON THERAPEUTICS PLC (HZNP) has a profitability rating of 8 / 10.
Can you provide the financial health for HZNP stock?
The financial health rating of HORIZON THERAPEUTICS PLC (HZNP) is 7 / 10.